Axonics Modulation Technologies (NSDQ:AXNX) announced today that NICE suggested using its r-SNM system in the UK. The National Institute for Health and Care Excellence (NICE) offers evidence-based guidance to the UK and, in guidance published last week, it recommended Axonics’ sacral neuromodulation (SNM) system for treating refractory overactive bladder for the country’s National Health Service (NHS). […]
U.K. National Institute for Health & Care Excellence (NICE)
The U.K.’s National Institute for Health and Care Excellence (NICE) recommended the sacral neuromodulation (SNM) system developed by Axonics Modulation Technologies (NSDQ:AXNX) for treating overactive bladder in its latest draft guidance. Axonics’ system is the only SNM device approved for full-body MRI scans without needing the device explanted, according to the company. The device itself is […]
Pulmonx and Olympus (TYO:7733) won a nod from a British health agency for the endobronchial valves they sell to treat severe emphysema. The U.K.’s National Institute for Health & Care Excellence updated its guidance for the valves, saying it considers the clinical evidence behind them sufficient to support routine use. The one-way valves, Pulmonx’s Zephyr and the Spiration […]
A British health watchdog reportedly plans to recommend that the National Health Service there ban vaginal mesh implants to treat pelvic organ prolapse, citing “serious but well-recognized safety concerns.” In recommending that the implants be limited to research use only, the U.K.’s National Institute for Health & Care Excellence said “evidence of long-term efficacy [for implants […]
The U.K.’s National Institute for Health & Care Excellence issued final guidance on HeartFlow‘s FFRct technology, which uses algorithms to generate 3D models of blood flows and can help diagnose heart disease. The British agency recommended the use of FFRct for patients with stable, recent-onset chest pain, finding that the technology is safe, has a high level of diagnostic […]
Regulators in the U.K. are reportedly poised to ban the use of metal-on-metal hip implants after finding unacceptably high rates of failure in a review of 17,000 cases.
The proposed ban, which would affect hospitals in the U.K.’s National Health Service, follows a review by the country’s National Institute for Health & Care Excellence that found failure rates as high as 43% for some of the implants, The Telegraph reported.